Crescent Biopharma Inc
Company Profile
Business description
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Contact
300 Fifth Avenue
WalthamMA02451
USAT: +1 617 430-5595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
44
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |